Curant Rare
Curant Rare is a US-based, Atlanta-headquartered specialty pharmacy and real-world evidence business unit of Curant Health, delivering high-touch patient care, insurance navigation, and proprietary RWE solutions for pharmaceutical manufacturers developing rare and ultra-rare disease therapies.
- Company typePrivate
- Founded2000
- HeadquartersAtlanta, United States
- Headcount—
- GTM type—
- OfferingServices
What Curant Rare does
Curant Rare is a specialized rare disease specialty pharmacy business unit of Curant Health, headquartered in Atlanta, GA, and launched in January 2025 to focus exclusively on rare and ultra-rare disease care. The company operates as a carve-out of Curant Health's broader Medication Care Management organization, leveraging 25+ years of parent-company operating history and 12 IRB-validated clinical studies with leading academic medical centers to deliver specialty pharmacy services to pharmaceutical manufacturers and their rare disease patient populations.
The company's core offering centers on its signature Medication Care Management (MCM) approach, which provides high-touch patient support, dedicated Patient Care Coordinators, insurance navigation, financial assistance, and curated educational resources throughout the rare disease journey. This care model is augmented by a proprietary Clinical Intelligence Platform offering real-time insights (RTI), referral visibility, adverse event monitoring, drug interaction detection, and Patient Reported Outcomes (PROs) collection for pharma partners. Notable technical components include the first-of-its-kind NPC Real-World Evidence System developed with IntraBio using the WeeFIM functional outcome scale, plus daily patient status reporting capabilities. The company also operates Expanded Access Programs (EAPs) supporting pre-approval therapy access.
Curant Rare monetizes through specialty pharmacy service fees for distribution, patient care coordination, and access facilitation, alongside RWE data monetization for pharma partners. Go-to-market is B2B enterprise field sales and strategic channel partnerships, with exclusive pharmacy partnerships secured for AQNEURSA (IntraBio, Niemann-Pick Type C), IWILFIN (US WorldMeds, neuroblastoma), and Corcept Therapeutics therapies, plus a strategic commercialization collaboration with Cencora. Pricing is not publicly disclosed, and revenue figures are not available in public materials, which is itself a data gap for potential investors.
Curant Rare firmographics
Firmographics- Name
- Curant Rare
- Legal name
- Curant Health
- Website
- https://curantrare.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Short description
- Curant Rare is a US-based, Atlanta-headquartered specialty pharmacy and real-world evidence business unit of Curant Health, delivering high-touch patient care, insurance navigation, and proprietary RWE solutions for pharmaceutical manufacturers developing rare and ultra-rare disease therapies.
- Ownership category
- akta.pro rank
Curant Rare industry classification
Industry- Product category
- Specialty Pharmacy Services
- NAICS
- Pharmacies and Drug Retailers (456110), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (45611)
- SIC
- Retail-Drug Stores And Proprietary Stores (5912)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
Keywords
Where Curant Rare is headquartered
LocationHeadquarters
- HQ city
- Atlanta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Curant Rare business model
Business model- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Specialty Pharmacy Services: Provides distribution, medication management, and patient care coordination services to pharmaceutical manufacturers. Generates revenue through service fees for comprehensive patient support, access facilitation, and care coordination.
- Real-World Evidence Solutions: Collects and analyzes patient-reported outcomes, treatment trends, and clinical data for pharma partners. Provides actionable insights demonstrating patient impact and program effectiveness.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Curant Rare product offering
Product offeringCore offering
Curant Rare is the rare-disease specialty pharmacy division of Curant Health, providing medication care management, real-time insights and real-world evidence generation, and expanded access program services for patients with rare and orphan diseases. The offering combines patient-level clinical pharmacy services with manufacturer-facing evidence and access services for limited-distribution rare-disease therapies.
Product overview
Curant Rare is a specialized rare disease specialty pharmacy business unit that provides a unified platform combining bespoke specialty pharmacy services with Real-World Evidence solutions. The core offering centers on their validated Medication Care Management® (MCM) approach, which delivers high-touch patient, caregiver, and provider support. This core service is augmented by proprietary Real-Time Insights (RTI) analytics platforms, Real-World Evidence (RWE) and Real-World Data (RWD) collection capabilities, and Expanded Access Program (EAP) support. The company offers dedicated patient support programs like IWILFIN Cares and has established exclusive pharmacy partnerships with pharmaceutical manufacturers including Corcept Therapeutics for distribution of rare disease therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Medication Care Management Ongoing clinical pharmacy services for rare-disease patients, including therapy monitoring, adherence support, side-effect management, and coordination with prescribers; designed for patients on orphan and limited-distribution therapies and for the biopharma manufacturers of those products.
- Real-Time Insights / Real-World Evidence Real-world data capture and evidence-generation services that produce therapy-outcome insights for biopharmaceutical manufacturers of rare-disease products, supporting value demonstration and post-marketing evidence needs.
- Expanded Access Programs Operational management of expanded access and limited-distribution programs that enable patients with rare diseases to access investigational or otherwise restricted therapies, delivered in partnership with biopharmaceutical sponsors.
Quantifiable outcome
- Aggregated adherence rate measured as Total PDC (Proportion of Days Covered) across all member populations
- +4 more outcomes
Companies that use Curant Rare
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Curant Rare technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Curant Rare partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- CencoracoreStrategic collaboration combining Cencora's global pharmaceutical logistics services and commercialization solutions (pharmacovigilance, market access support) with Curant Rare's specialty pharmacy services and omnichannel patient engagement solutions. The integrated solution aims to streamline rare disease therapy commercialization, optimize patient journeys, and expedite speed-to-therapy for pharmaceutical companies developing rare disease treatments.
- US WorldMedscoreExclusive pharmacy partnership for IWILFIN, the first and only FDA-approved oral maintenance therapy shown to cut the risk of high-risk neuroblastoma relapse in half. Curant Rare powers the IWILFIN Cares program with enhanced digital engagement, shipment visibility tools, bi-directional texting, and dedicated Patient Care Coordinators for high-risk neuroblastoma patients.
- Corcept TherapeuticscoreSpecialty pharmacy partnership providing personalized care, coordinated access to therapy, and comprehensive support to help patients and caregivers navigate treatment complexities. Services include dedicated Patient Care Coordinators, insurance navigation, financial assistance, shipment visibility with real-time tracking, and curated educational resources.
- IntraBiocoreExclusive specialty pharmacy partnership for AQNEURSA (levacetylleucine), the first FDA-approved stand-alone therapy for Niemann-Pick Disease Type C (NPC). Partnership also includes collaboration on real-world evidence generation using the WeeFIM scale, with poster presentation at World Orphan Drug Congress 2026 demonstrating functional outcomes in NPC patients.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Curant Rare competitors and assessment
Company assessmentBroad incumbents
- US Bioservices (AmerisourceBergen): US Bioservices is AmerisourceBergen's specialty pharmacy services platform providing high-touch patient support for complex and rare disease therapies. Comparable as a specialty pharmacy with rare disease focus but operating within a much larger distribution and services organization.
- Cencora (formerly AmerisourceBergen): Cencora is a global pharmaceutical services and distribution giant offering specialty distribution, patient services, and commercialization support for rare disease therapies. Already a Curant Rare strategic partner; comparable as a broad incumbent in the pharma services value chain.
- Optum Specialty Pharmacy: Optum Specialty (formerly including Diplomat Specialty Pharmacy, acquired by Optum) is one of the largest U.S. specialty pharmacy platforms with broad rare disease capabilities through a much larger portfolio. Serves the same patient populations but as part of a much broader healthcare services ecosystem, including payer-owned infrastructure.
- Walgreens Specialty Pharmacy: Walgreens Specialty Pharmacy (including CenterWell) provides nationwide specialty drug distribution and patient support services including for rare disease therapies. Comparable as a broad incumbent with rare disease capabilities but operates across many therapy areas.
- CVS Specialty (Caremark): CVS Specialty is the specialty pharmacy arm of CVS Health, providing rare disease therapy distribution and patient support services at massive scale via retail and mail-order channels. Operates in the same space but with significantly broader reach and payer integration.
Emerging players
- Medvantx: Medvantx is a specialty pharmacy focused on chronic, complex, and rare conditions with high-touch patient support services and pharma manufacturer partnerships. Comparable as a smaller, emerging specialty pharmacy with a similar patient-centric model for rare disease populations.
Direct peers
- AcariaHealth: AcariaHealth is a specialty pharmacy focused on complex and chronic conditions including rare diseases, providing patient support services, distribution, and clinical programs to pharma manufacturers. Comparable as a specialty pharmacy serving rare disease populations with pharma partnership model.
- Bioplus Specialty Pharmacy: Bioplus is a privately held specialty pharmacy focused on complex patient populations including rare disease, with services spanning distribution, adherence support, and care coordination. Comparable as a mid-sized specialty pharmacy targeting rare and complex therapies.
- Soleo Health: Soleo Health is a national specialty pharmacy and infusion services provider serving patients with complex and rare conditions, with similar high-touch care coordination and pharma partnership model. Comparable in patient-centric service delivery for complex therapy patients.
- PANTHERx Rare Pharmacy: PANTHERx Rare is a specialty pharmacy exclusively focused on rare and orphan disease therapies, offering high-touch patient support, distribution, and clinical services to pharma manufacturers. It is the closest direct competitor to Curant Rare in the rare disease specialty pharmacy niche with a comparable exclusive-partnership go-to-market model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Curant Rare compliance and trust
Trust signalCompliance5 records
Curant Rare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curant Rare leadership team
Management profileNumber of profiles
Profiles2 records
Curant Rare funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curant Rare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curant Rare
What does Curant Rare do?
Curant Rare is the rare-disease specialty pharmacy division of Curant Health, providing medication care management, real-time insights and real-world evidence generation, and expanded access program services for patients with rare and orphan diseases. The offering combines patient-level clinical pharmacy services with manufacturer-facing evidence and access services for limited-distribution rare-disease therapies.
Is Curant Rare a public or private company?
Curant Rare is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Curant Rare founded?
Curant Rare was founded in 2000.
Where is Curant Rare based?
Curant Rare is headquartered in Atlanta, United States, in the North America region.
How does Curant Rare make money?
Two revenue lines are on record. Specialty Pharmacy Services are the primary driver. The others are real-World Evidence Solutions.
Who are Curant Rare's main competitors?
Broad incumbents on record are US Bioservices (AmerisourceBergen), Cencora (formerly AmerisourceBergen), Optum Specialty Pharmacy, Walgreens Specialty Pharmacy and CVS Specialty (Caremark). Medvantx is listed as an emerging player. Direct peers are AcariaHealth, Bioplus Specialty Pharmacy, Soleo Health and PANTHERx Rare Pharmacy.
Does Curant Rare have an API?
No public API is recorded for Curant Rare.
What industry is Curant Rare in?
Curant Rare's product category is Specialty Pharmacy Services. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 456110 and its SIC code is 5912.